Search

Your search keyword '"Mehta, Rohtesh S."' showing total 20 results
Start Over Author "Mehta, Rohtesh S." Publication Year Range This year
Sorry, I don't understand your search. ×
20 results on '"Mehta, Rohtesh S."'

2. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis

Author

Malek, Alexandre E., Al-Juhaishi, Taha, Milton, Denái R., Ramdial, Jeremy L., Daher, May, Olson, Amanda L., Srour, Samer A., Alatrash, Gheath, Oran, Betul, Mehta, Rohtesh S., Khouri, Issa F., Bashir, Qaiser, Shah, Nina, Ciurea, Stefan O., Rondon, Gabriela, Maadani, Farzaneh, Hosing, Chitra, Marin, David, Kebriaei, Partow, Rezvani, Katayoun, Nieto, Yago, Anderlini, Paolo, Alousi, Amin M., Faisal, Muhammad Salman, Qazilbash, Muzaffar H., Popat, Uday R., Champlin, Richard E., Shpall, Elizabeth J., Mulanovich, Victor E., and Ahmed, Sairah

Published
2024
Full Text
View/download PDF

5. List of Contributors

Author

Rahman, Zaid Abdel, primary, Abutalib, Syed Ali, additional, Afrough, Aimaz, additional, Ahmed, Sairah, additional, Al-Juhaishi, Taha, additional, Alousi, Amin M, additional, Alsfeld, Leonard C., additional, Awan, Farrukh T., additional, Azhar, Ahsan, additional, Bashir, Qaiser, additional, Brown, Brandon Douglas, additional, Cao, Kai, additional, Champlin, Richard E., additional, Cherng, Hua-Jay J., additional, Ciurea, Stefan O., additional, Dabaja, Bouthaina, additional, Daher, May, additional, De Lima, Marcos, additional, Dillard, Christen M., additional, Fang, Penny, additional, Viña, Marcelo A. Fernández, additional, Ferreri, Christopher James, additional, Furqan, Fateeha, additional, Gagelmann, Nico, additional, Geethakumari, Praveen Ramakrishnan, additional, Ghanem, Sassine, additional, Greenbaum, Uri, additional, Gulbis, Alison M., additional, Haider, Ali, additional, Hamadani, Mehdi, additional, Handy, Victoria Wehr, additional, Hawkins, Misha C., additional, Heredia, Ella J. Ariza, additional, Hosing, Chitra, additional, Im, Jin Seon, additional, Jain, Nitin, additional, Jallouk, Andrew P, additional, Jankowski, Mika L., additional, Kale, Brandon J., additional, Kebriaei, Partow, additional, Khalil, Lana, additional, Khan, Irum, additional, Khazal, Sajad, additional, Kongtim, Piyanuch, additional, Lin, Paul, additional, Mahadeo, Kris M., additional, Malek, Alexandre E, additional, McGee, Kara, additional, Mehta, Rohtesh S., additional, Mulanovich, Victor Eduardo, additional, Munshi, Pashna N., additional, Nastoupil, Loretta J., additional, Neelapu, Sattva S, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Otegbeye, Folashade, additional, Patel, Akshat Maneesh, additional, Patel, Krina, additional, Paul, Prince, additional, Pemmaraju, Naveen, additional, Popat, Uday R, additional, Qazilbash, Muzaffar H., additional, Rafei, Hind, additional, Ragoonanan, Dristhi S, additional, Ramdial, Jeremy L., additional, Rezvani, Katayoun, additional, Rodriguez, Ana Avila, additional, Rondón, Gabriela, additional, Saengboon, Supawee, additional, Sanchez-Petitto, Gabriela, additional, Shigle, Terri Lynn, additional, Shpall, Elizabeth J., additional, Srour, Samer A., additional, Steiner, Raphael E., additional, Stolar, Karen R., additional, Strati, Paolo, additional, Szewczyk, Nicholas A., additional, Tanner, Mark R., additional, Tang, Kevin, additional, Thall, Peter F., additional, Tummala, Sudhakar, additional, Uzoka, Chukwuemeka, additional, Wallis, Whitney D., additional, Westin, Jason R., additional, Wilson, Nathaniel R., additional, Wu, Susan, additional, Guevara, Eduardo Yepez, additional, and Zou, Jun, additional

Published
2024
Full Text
View/download PDF

12. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation

Author

Saliba, Rima M., primary, Lee, Stephanie J., additional, Carpenter, Paul A, additional, Hill, Geoffrey R, additional, Lee, Catherine J., additional, Alousi, Amin, additional, Daher, May, additional, Chen, George, additional, Champlin, Richard E., additional, Rezvani, Katayoun, additional, Shpall, Elizabeth J., additional, and Mehta, Rohtesh S., additional

Published
2024
Full Text
View/download PDF

14. Effector Site Immune Dynamics in Refractory Chronic Graft-Versus-Host Disease: A Rockstar Trial Companion Study after Belumosudil Treatment.

Author

Sharma, Rubina, primary, Holtzman, Noa G., additional, Pusic, Dr. Iskra, additional, Cutler, Dr. Corey, additional, Treister, Nathaniel, additional, Mehta, Rohtesh S., additional, Alousi, Amin M., additional, Vigneswaran, Nadarajah, additional, Schueller, Olivier, additional, Macé, Sandrine, additional, Yao, Yu, additional, Ji, Ran, additional, Hu, Beifang, additional, Marshall, Kathy, additional, Blazar, Bruce R., additional, Lee, Stephanie J, additional, Pavletic, Dr. Steven Z., additional, and Mays, Jacqueline W., additional

Published
2024
Full Text
View/download PDF

15. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease

Author

Hayase, Eiko, Hayase, Tomo, Mukherjee, Akash, Stinson, Stuart C., Jamal, Mohamed A., Ortega, Miriam R., Sanchez, Christopher A., Ahmed, Saira S., Karmouch, Jennifer L., Chang, Chia-Chi, Flores, Ivonne I., McDaniel, Lauren K., Brown, Alexandria N., El-Himri, Rawan K., Chapa, Valerie A., Tan, Lin, Tran, Bao Q., Xiao, Yao, Fan, Christopher, Pham, Dung, Halsey, Taylor M., Jin, Yimei, Tsai, Wen-Bin, Prasad, Rishika, Glover, Israel K., Enkhbayar, Altai, Mohammed, Aqsa, Schmiester, Maren, King, Katherine Y., Britton, Robert A., Reddy, Pavan, Wong, Matthew C., Ajami, Nadim J., Wargo, Jennifer A., Shelburne, Samuel, Okhuysen, Pablo C., Liu, Chen, Fowler, Stephanie W., Conner, Margaret E., Katsamakis, Zoe, Smith, Natalie, Burgos da Silva, Marina, Ponce, Doris M., Peled, Jonathan U., van den Brink, Marcel R.M., Peterson, Christine B., Rondon, Gabriela, Molldrem, Jeffrey J., Champlin, Richard E., Shpall, Elizabeth J., Lorenzi, Philip L., Mehta, Rohtesh S., Martens, Eric C., Alousi, Amin M., and Jenq, Robert R.

Published
2024
Full Text
View/download PDF

19. Combined Effect of Unrelated Donor Age and HLA Peptide-Binding Motifs (PBM) Match Status on HCT Outcomes

Author

Mehta, Rohtesh S., Petersdorf, Effie W., Spellman, Stephen R., and Lee, Stephanie J.

Abstract

1.Older unrelated donor age and PBM-mismatching confer similarly adverse effects on OS and the impacts are additive2.Younger donors appear to negate the detrimental effect of PBM-mismatching in the unrelated donor HCT setting with CNI-based GVHD prophylaxis

Published
2024
Full Text
View/download PDF

20. Decreasing Chronic Graft-Versus-Host Disease rates in all populations.

Author

Carpenter PA, Gooley TA, Boiko JR, Lee CJ, Burroughs L, Mehta RS, Salit RB, Bhatt NS, Krakow EF, Dahlberg A, Yeh AC, Summers C, Ueda Oshima M, Petersdorf EW, Vo PT, Connelly-Smith L, and Lee SJ

Abstract

Since 2005 there has been steady decline in chronic graft-versus-host disease (cGVHD) at Fred Hutchinson Cancer Center (FHCC). To better understand this phenomenon, we studied the risk of cGVHD requiring systemic immunosuppression (cGVHD-IS) as a function of hematopoietic cell transplantation (HCT)-date in 3066 survivors from 2005 through 2019. Cox regression models were fit to assess associations of HCT-date (as a continuous linear variable) with cause-specific hazards of cGVHD, using unadjusted and adjusted models. Median follow-up for study subjects was 7.0 years (range, 1.0-17.2). Two-year probabilities of cGVHD-IS declined among all survivors from 45-52% (2005-2007) to approximately 40% (2008-2012) and then further to ~26% by 2017. A decline was also observed when the analysis was restricted to 502 pediatric survivors, with cGVHD-IS probabilities being <10% since 2013. Among 305 adult and pediatric survivors who were transplanted for nonmalignant diseases, cGVHD rates showed greater fluctuation but remained <20% after 2016. Each 5-year increase in HCT-date was associated with a 27% decrease in the cause-specific hazard of cGVHD (unadjusted hazard ratio [HR] 0.73; 95% confidence interval [CI] 0.68-0.78, p<.0001); the HR was 0.81 (95% CI 0.75-0.87, p<.0001) even after adjusting for various factors (age, donor/stem-cell source, race, sex, conditioning intensity, GVHD prophylaxis, among others) that could lead to cGVHD reduction. The decline in cGVHD was not fully explained by demographic shifts and greater use of HCT approaches generally associated with lower cGVHD rates. This observation underscores that single-cohort cGVHD-prevention studies should use contemporaneous and not historical controls for comparisons., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results